BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17525875)

  • 1. Ketamine and the potential role for rapid-acting antidepressant medications.
    Krystal JH
    Swiss Med Wkly; 2007 Apr; 137(15-16):215-6. PubMed ID: 17525875
    [No Abstract]   [Full Text] [Related]  

  • 2. Blocking NMDA receptor at rest: a possible alleviation of depression.
    Lu W
    Acta Pharmacol Sin; 2011 Sep; 32(9):1087-8. PubMed ID: 21804573
    [No Abstract]   [Full Text] [Related]  

  • 3. N-methyl-D-aspartate glutamate receptor antagonists and the promise of rapid-acting antidepressants.
    Krystal JH
    Arch Gen Psychiatry; 2010 Nov; 67(11):1110-1. PubMed ID: 21041611
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms.
    Kato T; Duman RS
    Pharmacol Biochem Behav; 2020 Jan; 188():172827. PubMed ID: 31733218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketamine for Treatment-Resistant Depression: a New Advocate.
    Pérez-Esparza R
    Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketamine: A Paradigm Shift for Depression Research and Treatment.
    Krystal JH; Abdallah CG; Sanacora G; Charney DS; Duman RS
    Neuron; 2019 Mar; 101(5):774-778. PubMed ID: 30844397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ketamine and phencyclidine: the good, the bad and the unexpected.
    Lodge D; Mercier MS
    Br J Pharmacol; 2015 Sep; 172(17):4254-76. PubMed ID: 26075331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.
    Lepow L; Luckenbaugh DA; Park L; Henter ID; Zarate CA
    J Psychiatr Res; 2017 Mar; 86():55-57. PubMed ID: 27914292
    [No Abstract]   [Full Text] [Related]  

  • 11. Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.
    Hashimoto K
    Psychopharmacology (Berl); 2014 Oct; 231(20):4081-2. PubMed ID: 25189793
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid antidepressant effects: moving right along.
    Martinowich K; Jimenez DV; Zarate CA; Manji HK
    Mol Psychiatry; 2013 Aug; 18(8):856-63. PubMed ID: 23689537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.
    Machado-Vieira R; Yuan P; Brutsche N; DiazGranados N; Luckenbaugh D; Manji HK; Zarate CA
    J Clin Psychiatry; 2009 Dec; 70(12):1662-6. PubMed ID: 19744406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder.
    Blier P
    Biol Psychiatry; 2013 Aug; 74(4):238-9. PubMed ID: 23885752
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to Zhang and Ho: Addressing Ketamine's Use in Depression.
    Newport DJ; Nemeroff CB
    Am J Psychiatry; 2016 Apr; 173(4):431-2. PubMed ID: 27035536
    [No Abstract]   [Full Text] [Related]  

  • 16. Scopolamine and ketamine: evidence of convergence?
    Monteggia LM; Kavalali ET
    Biol Psychiatry; 2013 Nov; 74(10):712-3. PubMed ID: 24144324
    [No Abstract]   [Full Text] [Related]  

  • 17. NMDA antagonist treatment of depression.
    Williams NR; Schatzberg AF
    Curr Opin Neurobiol; 2016 Feb; 36():112-7. PubMed ID: 26687375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there anything really novel on the antidepressant horizon?
    Murrough JW; Charney DS
    Curr Psychiatry Rep; 2012 Dec; 14(6):643-9. PubMed ID: 22996298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical Appraisal of Existing Ketamine Trials: Existing Limitations and Limited Applicability for Treatment.
    Zhang MW; Ho R
    Am J Psychiatry; 2016 Apr; 173(4):431. PubMed ID: 27035535
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of ketamine and its metabolites as antidepressants.
    Hess EM; Riggs LM; Michaelides M; Gould TD
    Biochem Pharmacol; 2022 Mar; 197():114892. PubMed ID: 34968492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.